Treatment of Metastatic Renal Cell Carcinoma: A Comprehensive Review and Indian Perspective
Asian Oncology Research Journal,
Page 16-40
Abstract
Renal cell carcinoma (RCC) is the eighth most common type of cancer, with more than one-third of patients having metastases when first diagnosed. There is a paradigm shift in metastatic RCC (mRCC) management with the advent of newer therapy options. The development of new innovative diagnostic and therapeutic tools has improved the prognosis of patients with advanced-stage disease. Inclusion of agents targeting the vascular endothelial growth factor (VEGF) pathway (predominantly VEGFR-directed tyrosine kinase inhibitors (TKIs)), immune-checkpoint inhibitors (ICIs) and parallel efforts to uncover new targets unveil the underlying biological differences between heterogeneous disease subtypes. Thus, new systemic therapies have become increasingly complex and optimising patient selection and treatment sequence for better patient outcomes has become crucial. This review provides a comprehensive overview of advances in the treatment landscape, emphasising the importance of individualised treatment approaches for specific subgroups of patients and also discusses the Indian perspective on the management of metastatic renal cell carcinoma with real-world case studies.
Keywords:
- Metastatic RCC
- targeted therapy
- immunotherapy
- systemic therapy
How to Cite
Biswas, B., Gupta, S., Warrier, N. K., Patil, T., & Patil, S. (2022). Treatment of Metastatic Renal Cell Carcinoma: A Comprehensive Review and Indian Perspective. Asian Oncology Research Journal, 5(3), 16-40. Retrieved from https://journalaorj.com/index.php/AORJ/article/view/67
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for clInicians. 2021;71(3):209-49.
Milanetto AC, Morelli L, Di Franco G, David A, Campra D, De Paolis P, Pasquali C. A plea for surgery in pancreatic metastases from renal cell carcinoma: Indications and outcome from a multicenter surgical experience. Journal of Clinical Medicine. 2020;9(10):3278.
Alaghehbandan R, Perez Montiel D, Luis AS, Hes O. Molecular genetics of renal cell tumors: A practical diagnostic approach. Cancers. 2019;12(1):85.
Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA: A Cancer Journal for Clinicians. 2017;67(6):507-24.
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: Results from a large, multicenter study. Journal of Clinical Oncology. 2009;27(34):5794-9.
Kotecha RR, Motzer RJ, Voss MH. Towards individualised therapy for metastatic renal cell carcinoma. Nature reviews Clinical Oncology. 2019;16(10):621-33.
Libertino JA, Gee JR. Renal Cancer. Springer International Publishing; 2020.
Powles T. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up1. Annals of Oncology. 2021;32(3):422-3.
Yoshino T, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, Faud I. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Annals of Oncology. 2021;32(12):1496-510.
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 1999;17(8):2530.
Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Cancer. 2018;124(18):3677-83.
Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK. Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: characterisation of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013;119(16):2999-3006.
Noe A, de Bruijn RE, Blank C, Horenblas S, Haanen J, Bex A. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World Journal of Urology. 2016;34(8):1067-72.
Doppalapudi SK, Leopold ZR, Thaper A, Kaldany A, Chua K, Patel HV, Srivastava A, Singer EA. Clearing up clear cell: Clarifying the Immuno-Oncology treatment landscape for metastatic clear cell RCC. Cancers. 2021;13(16):4140.
Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: Results from the International mRCC Database Consortium. Clinical Genitourinary Cancer. 2015;13(2):150-5.
Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D. Is it possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with an intermediate or poor prognosis?. Clinical Genitourinary Cancer. 2018;16(5):355-9.
Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ. Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to international metastatic renal cell carcinoma database consortium risk group. Clinical Genitourinary Cancer. 2018;16(4):298-304.
Sella A, Michaelson MD, Matczak E, Simantov R, Lin X, Figlin RA. Heterogeneity of patients with intermediate-prognosis metastatic renal cell carcinoma treated with sunitinib. Clinical Genitourinary Cancer. 2017;15(2):291-9.
Kim JK, Kim SH, Song MK, Joo J, Seo SI, Kwak C, Jeong CW, Song C, Hwang EC, Seo IY, Lee H. Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. Cancer medicine. 2019;8(7):3401-10.
Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. The Lancet Oncology. 2016;17(9):1317-24.
Guida A, Le Teuff G, Alves C, Colomba E, Di Nunno V, Derosa L, Flippot R, Escudier B, Albiges L. Identification of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. Oncotarget. 2020;11(49):4582.
Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localised renal tumors under active surveillance. Cancer. 2009;115(13):2844-52.
Harrison MR, Costello BA, Bhavsar NA, Vaishampayan U, Pal SK, Zakharia Y, Jim HS, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer. 2021;127(13):2204-12.
Tenold M, Ravi P, Kumar M, Bowman A, Hammers H, Choueiri TK, Lara Jr PN. Current approaches to the treatment of advanced or metastatic renal cell carcinoma. American Society of Clinical Oncology Educational Book. 2020;40:187-96.
Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, Tzannis K, Kontovinis L, Stravodimos K, Papatsoris A, Mitropoulos D. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. The Oncologist. 2017;22(6):667-79.
Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144-50.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007;356(22):2271-81.
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton Jr JR, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New England Journal of Medicine. 2001;345(23):1655-9.
Mickisch GH, Garin A, Van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. The Lancet. 2001;358(9286):966-70.
Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. The Journal of Urology. 2004;171(3):1071-6.
Lara Jr PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. The Journal of Urology. 2009;181(2):512-7.
Logan T, McDermott DF, Dutcher JP, Makhson A, Mikulas J, Berkenblit A, Galand L, Krygowski M, Hudes GR. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. Journal of Clinical Oncology. 2008;26(15_suppl):5050.
Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. InUrologic Oncology: Seminars and Original Investigations. 2015;33(8):339-e9. Elsevier.
Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW. Treatment of patients with metastatic renal cell cancer: A RAND Appropriateness Panel. Cancer. 2006;107(10):2375-83.
Bex A, Ljungberg B, van Poppel H, Powles T, European Association of Urology. The role of cytoreductive nephrectomy: European Association of Urology Recommendations in 2016. European Urology. 2016;70(6):901-5.
Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer. 2010;116(14):3378-88.
Bex A, Horenblas S, Meinhardt W, Verra N, De Gast GC. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. European Urology. 2002;42(6):570-6.
Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873-82.
Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. The Journal of Urology. 2008;180(3):873-8.
Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. Journal of Clinical Oncology. 1998;16(6):2261-6.
Hara T, Miyake H, Hinata N, Fujisawa M. Inhibition of tumor growth and sensitisation to Sunitinib by RNA interference targeting programmed death-ligand 1 in mouse renal cell carcinoma RenCa model. Anticancer Research. 2019;39(9):4737-42.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2019;380(12):1116-27.
Deng H, Huang Y, Hong Z, Yuan X, Cao Z, Wei Y, Zhang W. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis. BMC Cancer. 2019;19(1):1-2.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2019;380(12):1103-15.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine. 2007;356(2):115-24.
Verman R, Lara PN. Cytokines in the Management of Advanced Renal Cell Cancer. InKidney Cancer. 2015;245-258. Springer, Cham.
Escudier B, Tannir NM, McDermott DF, Frontera OA, Melichar B, Plimack ER, Barthelemy P, George S, Neiman V, Porta C, Choueiri TK. CheckMate 214: efficacy and safety of nivolumab+ ipilimumab (N+ I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology. 2017;28:v621-2.
Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of Oncology. 2020;31(8):1030-9..
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2021;384(9):829-41.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New England Journal of Medicine. 2021;384(14):1289-300.
McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, Signoretti S, Hirsch MS, Steinharter JA, Bakouny Z, Flippot R. Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features. Journal of Clinical Oncology. 2020;38(1):63.
Noronha V, Abraham G, Patil V, Joshi A, Menon N, Mahajan A, Janu A, Jain S, Talreja VT, Kapoor A, Kumar Singh G. A real‐world data of Immune checkpoint inhibitors in solid tumors from India. Cancer Medicine. 2021;10(5):1525-34.
Zanwar S, Joshi A, Noronha V, Patil VM, Sable N, Popat P, Menon S, Kothari R, Bhargava P, Kapoor A, Prabhash K. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry-based analysis. Indian Journal of Cancer. 2016;53(4):579.
Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D. CheckMate 025 randomised phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. European urology. 2017;72(6):962-71.
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592–603.
Grüllich C. Cabozantinib: multi-kinase inhibitor of MET, AXL, RET, and VEGFR2. Small Molecules in Oncology. 2018;67-75.
Zschäbitz S, Grüllich C. Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET. Small Molecules in Oncology. 2018;187-98.
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. The Lancet Oncology. 2015;16(15):1473-82.
Abbas W, Aggarwal A, Pankaj P, Jain R. Real-world data of second-line immunotherapy in metastatic clear cell renal cell carcinoma: A retrospective study. Cancer Research, Statistics, and Treatment. 2021;4(1):55.
Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. European Urology. 2017;72(3):368-76.
Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. The Lancet Oncology. 2019;20(10): 1386-94.
Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M. Outcomes based on prior therapy in the phase 3 Meteor trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British journal of cancer. 2018;119(6):663-9.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine. 2015;373(19):1803-13.
Sheng IY, Ornstein MC. Ipilimumab and nivolumab as first-line treatment of patients with renal cell carcinoma: the evidence to date. Cancer Management and Research. 2020;12:4871.
Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Annals of Oncology. 2016;27(7):1304-11.
Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. British Journal of Cancer. 2014;110(12):2821-8.
Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW. Phase II randomised trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2014;32(25):2765.
Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine; 2018.
Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie R, Bapat U, Ye W, Jain RK. A single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma. European Urology. 2021;80(2):162-70.
Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Lim ZD, Tamboli P, Rao P. Everolimus versus sunitinib prospective evaluation in metastatic non–clear cell renal cell carcinoma (ESPN): A randomised multicenter phase 2 trial. European Urology. 2016;69(5):866-74.
Parikh M, Harris J, Alpajaro SI, Lara PN, Evans CP. Defining an Individualised Treatment Strategy for Metastatic Renal Cancer. InRenal Cancer. 2020;437-452. Springer, Cham.
Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. Journal for Immunotherapy of Cancer. 2018;6(1):1-7.
Pal SK, Tangen C, Thompson Jr IM, Balzer-Haas N, George DJ, Heng DY, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. The Lancet. 2021;397(10275):695-703.
Choueiri TK, Heng DY, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, Ottesen LH, Frigault MM, L'Hernault A, Szijgyarto Z, Signoretti S. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomised clinical trial. JAMA Oncology. 2020;6(8):1247-55.
Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncology Practice. 2022;18(3):187-96.
Kidney Cancer NCCN Clinical Practice Guidelines in Oncology.
Availablee:https://www.nccn.org/ professionals/physician_gls/pdf/kidney.pdf (accessed on 15 December 2019)
Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, Califano R, Carcereny E, Griffiths R, Paz-Ares L, Duchnowska R. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer. 2020;127:160-72.
Ernst DS, McConkey H, Liu L, Butler MO, Petrella T, Baetz T, Koneru R, Song X, Cheng T, Smylie MG, Rajagopal S. Utilization of real-world data to assess the effectiveness of immune checkpoint inhibitors (ICIs) in elderly patients with metastatic melanoma. Annals of Oncology. 2019;30:v553.
Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, Agarwal N. Treatment of metastatic renal cell carcinoma in older patients: a network meta-analysis. Journal of Geriatric Oncology. 2019;10(1):149-54.
McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—A meta-analysis. European Journal of Cancer. 2018;105:1-9.
Kanz BA, Pollack MH, Johnpulle R, Puzanov I, Horn L, Morgans A, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. Journal for Immunotherapy of Cancer. 2016;4(1):1-6.
Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. The Journal of Clinical Pharmacology. 2010;50(4):472-81.
Josephs DH, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, Mcdermott DF, Powles T, Harper PG, Chowdhury S. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis. Journal of Clinical Oncology. 2009;27(15_suppl):5109.
Gupta S, Parsa V, Heilbrun LK, Smith DW, Dickow B, Heath E, Vaishampayan U. Safety and efficacy of targeted agents in metastatic kidney cancer patients with renal dysfunction. Anti-Cancer Drugs. 2011;22(8):794.
Achkar T, Maranchie JK, Appleman LJ. Metastasectomy in advanced renal cell carcinoma: a systematic review. Kidney Cancer. 2019;3(1):31-40.
Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH. NCCN guidelines insights: Kidney cancer, version 1.2021: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network. 2020;18(9):1160-70.
Chapin BF, Delacroix Jr SE, Culp SH, Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. European Urology. 2011;60(5):964-71.
Appleman LJ, Puligandla M, Pal SK, Harris W, Agarwal N, Costello BA, Ryan CW, Pins M, Kolesar J, Vaena DA, Parikh RA. Randomised, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
Wardak Z, Christie A, Bowman A, Stojadinovic S, Nedzi L, Barnett S, Patel T, Mickey B, Whitworth T, Hannan R, Brugarolas J. Stereotactic radiosurgery for multiple brain metastases from renal-cell carcinoma. Clinical Genitourinary Cancer. 2019;17(2):e273-80.
Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F, Tosi D, Oudard S, Blanc E, Ferlay C, Négrier S. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clinical Genitourinary Cancer. 2014;12(1): 50-4.
Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. Journal of Clinical Oncology. 2019;37(23): 2008-16.
Parikh M, Bajwa P. Immune checkpoint inhibitors in the treatment of renal cell carcinoma. InSeminars in nephrology 2020;40(1):76-85. WB Saunders.
Milanetto AC, Morelli L, Di Franco G, David A, Campra D, De Paolis P, Pasquali C. A plea for surgery in pancreatic metastases from renal cell carcinoma: Indications and outcome from a multicenter surgical experience. Journal of Clinical Medicine. 2020;9(10):3278.
Alaghehbandan R, Perez Montiel D, Luis AS, Hes O. Molecular genetics of renal cell tumors: A practical diagnostic approach. Cancers. 2019;12(1):85.
Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA: A Cancer Journal for Clinicians. 2017;67(6):507-24.
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: Results from a large, multicenter study. Journal of Clinical Oncology. 2009;27(34):5794-9.
Kotecha RR, Motzer RJ, Voss MH. Towards individualised therapy for metastatic renal cell carcinoma. Nature reviews Clinical Oncology. 2019;16(10):621-33.
Libertino JA, Gee JR. Renal Cancer. Springer International Publishing; 2020.
Powles T. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up1. Annals of Oncology. 2021;32(3):422-3.
Yoshino T, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, Faud I. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Annals of Oncology. 2021;32(12):1496-510.
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 1999;17(8):2530.
Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Cancer. 2018;124(18):3677-83.
Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK. Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: characterisation of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013;119(16):2999-3006.
Noe A, de Bruijn RE, Blank C, Horenblas S, Haanen J, Bex A. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World Journal of Urology. 2016;34(8):1067-72.
Doppalapudi SK, Leopold ZR, Thaper A, Kaldany A, Chua K, Patel HV, Srivastava A, Singer EA. Clearing up clear cell: Clarifying the Immuno-Oncology treatment landscape for metastatic clear cell RCC. Cancers. 2021;13(16):4140.
Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: Results from the International mRCC Database Consortium. Clinical Genitourinary Cancer. 2015;13(2):150-5.
Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D. Is it possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with an intermediate or poor prognosis?. Clinical Genitourinary Cancer. 2018;16(5):355-9.
Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ. Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to international metastatic renal cell carcinoma database consortium risk group. Clinical Genitourinary Cancer. 2018;16(4):298-304.
Sella A, Michaelson MD, Matczak E, Simantov R, Lin X, Figlin RA. Heterogeneity of patients with intermediate-prognosis metastatic renal cell carcinoma treated with sunitinib. Clinical Genitourinary Cancer. 2017;15(2):291-9.
Kim JK, Kim SH, Song MK, Joo J, Seo SI, Kwak C, Jeong CW, Song C, Hwang EC, Seo IY, Lee H. Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. Cancer medicine. 2019;8(7):3401-10.
Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. The Lancet Oncology. 2016;17(9):1317-24.
Guida A, Le Teuff G, Alves C, Colomba E, Di Nunno V, Derosa L, Flippot R, Escudier B, Albiges L. Identification of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. Oncotarget. 2020;11(49):4582.
Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localised renal tumors under active surveillance. Cancer. 2009;115(13):2844-52.
Harrison MR, Costello BA, Bhavsar NA, Vaishampayan U, Pal SK, Zakharia Y, Jim HS, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer. 2021;127(13):2204-12.
Tenold M, Ravi P, Kumar M, Bowman A, Hammers H, Choueiri TK, Lara Jr PN. Current approaches to the treatment of advanced or metastatic renal cell carcinoma. American Society of Clinical Oncology Educational Book. 2020;40:187-96.
Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, Tzannis K, Kontovinis L, Stravodimos K, Papatsoris A, Mitropoulos D. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. The Oncologist. 2017;22(6):667-79.
Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144-50.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007;356(22):2271-81.
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton Jr JR, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New England Journal of Medicine. 2001;345(23):1655-9.
Mickisch GH, Garin A, Van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. The Lancet. 2001;358(9286):966-70.
Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. The Journal of Urology. 2004;171(3):1071-6.
Lara Jr PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. The Journal of Urology. 2009;181(2):512-7.
Logan T, McDermott DF, Dutcher JP, Makhson A, Mikulas J, Berkenblit A, Galand L, Krygowski M, Hudes GR. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. Journal of Clinical Oncology. 2008;26(15_suppl):5050.
Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. InUrologic Oncology: Seminars and Original Investigations. 2015;33(8):339-e9. Elsevier.
Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW. Treatment of patients with metastatic renal cell cancer: A RAND Appropriateness Panel. Cancer. 2006;107(10):2375-83.
Bex A, Ljungberg B, van Poppel H, Powles T, European Association of Urology. The role of cytoreductive nephrectomy: European Association of Urology Recommendations in 2016. European Urology. 2016;70(6):901-5.
Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer. 2010;116(14):3378-88.
Bex A, Horenblas S, Meinhardt W, Verra N, De Gast GC. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. European Urology. 2002;42(6):570-6.
Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873-82.
Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. The Journal of Urology. 2008;180(3):873-8.
Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. Journal of Clinical Oncology. 1998;16(6):2261-6.
Hara T, Miyake H, Hinata N, Fujisawa M. Inhibition of tumor growth and sensitisation to Sunitinib by RNA interference targeting programmed death-ligand 1 in mouse renal cell carcinoma RenCa model. Anticancer Research. 2019;39(9):4737-42.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2019;380(12):1116-27.
Deng H, Huang Y, Hong Z, Yuan X, Cao Z, Wei Y, Zhang W. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis. BMC Cancer. 2019;19(1):1-2.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2019;380(12):1103-15.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine. 2007;356(2):115-24.
Verman R, Lara PN. Cytokines in the Management of Advanced Renal Cell Cancer. InKidney Cancer. 2015;245-258. Springer, Cham.
Escudier B, Tannir NM, McDermott DF, Frontera OA, Melichar B, Plimack ER, Barthelemy P, George S, Neiman V, Porta C, Choueiri TK. CheckMate 214: efficacy and safety of nivolumab+ ipilimumab (N+ I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology. 2017;28:v621-2.
Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of Oncology. 2020;31(8):1030-9..
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2021;384(9):829-41.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New England Journal of Medicine. 2021;384(14):1289-300.
McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, Signoretti S, Hirsch MS, Steinharter JA, Bakouny Z, Flippot R. Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features. Journal of Clinical Oncology. 2020;38(1):63.
Noronha V, Abraham G, Patil V, Joshi A, Menon N, Mahajan A, Janu A, Jain S, Talreja VT, Kapoor A, Kumar Singh G. A real‐world data of Immune checkpoint inhibitors in solid tumors from India. Cancer Medicine. 2021;10(5):1525-34.
Zanwar S, Joshi A, Noronha V, Patil VM, Sable N, Popat P, Menon S, Kothari R, Bhargava P, Kapoor A, Prabhash K. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry-based analysis. Indian Journal of Cancer. 2016;53(4):579.
Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D. CheckMate 025 randomised phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. European urology. 2017;72(6):962-71.
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592–603.
Grüllich C. Cabozantinib: multi-kinase inhibitor of MET, AXL, RET, and VEGFR2. Small Molecules in Oncology. 2018;67-75.
Zschäbitz S, Grüllich C. Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET. Small Molecules in Oncology. 2018;187-98.
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. The Lancet Oncology. 2015;16(15):1473-82.
Abbas W, Aggarwal A, Pankaj P, Jain R. Real-world data of second-line immunotherapy in metastatic clear cell renal cell carcinoma: A retrospective study. Cancer Research, Statistics, and Treatment. 2021;4(1):55.
Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. European Urology. 2017;72(3):368-76.
Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. The Lancet Oncology. 2019;20(10): 1386-94.
Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M. Outcomes based on prior therapy in the phase 3 Meteor trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British journal of cancer. 2018;119(6):663-9.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine. 2015;373(19):1803-13.
Sheng IY, Ornstein MC. Ipilimumab and nivolumab as first-line treatment of patients with renal cell carcinoma: the evidence to date. Cancer Management and Research. 2020;12:4871.
Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Annals of Oncology. 2016;27(7):1304-11.
Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. British Journal of Cancer. 2014;110(12):2821-8.
Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW. Phase II randomised trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2014;32(25):2765.
Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine; 2018.
Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie R, Bapat U, Ye W, Jain RK. A single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma. European Urology. 2021;80(2):162-70.
Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Lim ZD, Tamboli P, Rao P. Everolimus versus sunitinib prospective evaluation in metastatic non–clear cell renal cell carcinoma (ESPN): A randomised multicenter phase 2 trial. European Urology. 2016;69(5):866-74.
Parikh M, Harris J, Alpajaro SI, Lara PN, Evans CP. Defining an Individualised Treatment Strategy for Metastatic Renal Cancer. InRenal Cancer. 2020;437-452. Springer, Cham.
Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. Journal for Immunotherapy of Cancer. 2018;6(1):1-7.
Pal SK, Tangen C, Thompson Jr IM, Balzer-Haas N, George DJ, Heng DY, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. The Lancet. 2021;397(10275):695-703.
Choueiri TK, Heng DY, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, Ottesen LH, Frigault MM, L'Hernault A, Szijgyarto Z, Signoretti S. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomised clinical trial. JAMA Oncology. 2020;6(8):1247-55.
Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncology Practice. 2022;18(3):187-96.
Kidney Cancer NCCN Clinical Practice Guidelines in Oncology.
Availablee:https://www.nccn.org/ professionals/physician_gls/pdf/kidney.pdf (accessed on 15 December 2019)
Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, Califano R, Carcereny E, Griffiths R, Paz-Ares L, Duchnowska R. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer. 2020;127:160-72.
Ernst DS, McConkey H, Liu L, Butler MO, Petrella T, Baetz T, Koneru R, Song X, Cheng T, Smylie MG, Rajagopal S. Utilization of real-world data to assess the effectiveness of immune checkpoint inhibitors (ICIs) in elderly patients with metastatic melanoma. Annals of Oncology. 2019;30:v553.
Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, Agarwal N. Treatment of metastatic renal cell carcinoma in older patients: a network meta-analysis. Journal of Geriatric Oncology. 2019;10(1):149-54.
McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—A meta-analysis. European Journal of Cancer. 2018;105:1-9.
Kanz BA, Pollack MH, Johnpulle R, Puzanov I, Horn L, Morgans A, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. Journal for Immunotherapy of Cancer. 2016;4(1):1-6.
Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. The Journal of Clinical Pharmacology. 2010;50(4):472-81.
Josephs DH, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, Mcdermott DF, Powles T, Harper PG, Chowdhury S. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis. Journal of Clinical Oncology. 2009;27(15_suppl):5109.
Gupta S, Parsa V, Heilbrun LK, Smith DW, Dickow B, Heath E, Vaishampayan U. Safety and efficacy of targeted agents in metastatic kidney cancer patients with renal dysfunction. Anti-Cancer Drugs. 2011;22(8):794.
Achkar T, Maranchie JK, Appleman LJ. Metastasectomy in advanced renal cell carcinoma: a systematic review. Kidney Cancer. 2019;3(1):31-40.
Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH. NCCN guidelines insights: Kidney cancer, version 1.2021: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network. 2020;18(9):1160-70.
Chapin BF, Delacroix Jr SE, Culp SH, Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. European Urology. 2011;60(5):964-71.
Appleman LJ, Puligandla M, Pal SK, Harris W, Agarwal N, Costello BA, Ryan CW, Pins M, Kolesar J, Vaena DA, Parikh RA. Randomised, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
Wardak Z, Christie A, Bowman A, Stojadinovic S, Nedzi L, Barnett S, Patel T, Mickey B, Whitworth T, Hannan R, Brugarolas J. Stereotactic radiosurgery for multiple brain metastases from renal-cell carcinoma. Clinical Genitourinary Cancer. 2019;17(2):e273-80.
Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F, Tosi D, Oudard S, Blanc E, Ferlay C, Négrier S. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clinical Genitourinary Cancer. 2014;12(1): 50-4.
Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. Journal of Clinical Oncology. 2019;37(23): 2008-16.
Parikh M, Bajwa P. Immune checkpoint inhibitors in the treatment of renal cell carcinoma. InSeminars in nephrology 2020;40(1):76-85. WB Saunders.
-
Abstract View: 168 times
PDF Download: 46 times
Download Statistics
Downloads
Download data is not yet available.
